Evidence map›Paper›PMID 36248858›Full record

ArticleFrontiers in immunology2022

Targeting hypoxia-induced tumor stemness by activating pathogen-induced stem cell niche defense.

Seema Bhuyan, Bidisha Pal, Lekhika Pathak, Partha Jyoti Saikia, Shirsajit Mitra, Sukanya Gayan, Reza Bayat Mokhtari, Hong Li, Chilakamarti V Ramana, Debabrat Baishya and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Seema BhuyanDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Research Park, Indian Institute of Technology, Guwahati, India.
Bidisha PalDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Research Park, Indian Institute of Technology, Guwahati, India.
Lekhika PathakDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Research Park, Indian Institute of Technology, Guwahati, India.
Partha Jyoti SaikiaDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Research Park, Indian Institute of Technology, Guwahati, India.
Shirsajit MitraDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Research Park, Indian Institute of Technology, Guwahati, India.
Sukanya GayanDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Research Park, Indian Institute of Technology, Guwahati, India.
Reza Bayat MokhtariDepartment of Immunology and Infectious Diseases, Forsyth Institute, Cambridge, MA, United States.
Hong LiDepartment of Immunology and Infectious Diseases, Forsyth Institute, Cambridge, MA, United States.
Chilakamarti V RamanaDepartment of Experimental Therapeutics, Thoreau Laboratory for Global Health, M2D2, University of Massachusetts, Lowell, MA, United States.
Debabrat BaishyaDepartment of Bioengineering and Technology, Gauhati University, Guwahati, India.
Bikul DasDepartment of Cancer and Stem Cell Biology, KaviKrishna Laboratory, Research Park, Indian Institute of Technology, Guwahati, India.
Indian Institute of Technology Guwahati · INUniversity of Massachusetts Lowell · USGauhati University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor hypoxia and oxidative stress reprograms cancer stem cells (CSCs) to a highly aggressive and inflammatory phenotypic state of tumor stemness. Previously, we characterized tumor stemness phenotype in the ATP Binding Cassette Subfamily G Member 2 (ABCG2)-positive migratory side population (SPm) fraction of CSCs exposed to extreme hypoxia followed by reoxygenation. Here, we report that post-hypoxia/reoxygenation SPm+/ABCG2+ CSCs exerts defense against pathogen invasion that involves bystander apoptosis of non-infected CSCs. In an

Indexed as

HMGB1 ProteinStem Cell NicheAdenosine TriphosphateAnimalsBCG VaccineCell Line, TumorCulture Media, ConditionedEpithelial Cell Adhesion MoleculeHumansHypoxiaMiceNeoplastic Stem CellsToll-Like Receptor 2Tumor Suppressor Protein p53Adenosine TriphosphateBCG VaccineCulture Media, ConditionedEpithelial Cell Adhesion MoleculeHMGB1 ProteinToll-Like Receptor 2Tumor Suppressor Protein p53Altruistic Stem Cells (ASCs)Bacillus calmette guerinCancer Stem Cells (CSCs)Stem cell nicheTumor hypoxia and oxidative stress microenvironmentTumor stemness

Identifiers

PMID36248858
PMCPMC9559576
OpenAlexW4297996108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.